

CURRICULUM VITAE

NAME: Stamatis-Nick C. Liossis, M.D.

MAILING ADDRESS:

(Business) Division of Rheumatology, Department of Medicine, University Hospital of Patras, 265 00 Rion, GREECE.

(Home) 2 Momferatou & Somerset St, GR 26504 Rion, GREECE.

TEL: +30-2613 603 693 (Office), + 30-2610-993 197 (Home), + 30-97-7066105 (Cell)

E-Mail: snliossis@med.upatras.gr; sliossis@hotmail.com

PERSONAL INFORMATION

Date of birth: February 26, 1962

Place of birth: Hamilton, Ontario, Canada

Citizenship: Canadian/Greek

EDUCATION

1979-1985: M.D. Degree, Medical School, University of Patras, Patras, Greece.

1995-1999: Ph.D. Degree, Medical School, University of Patras, Patras, Greece.

BOARD CERTIFICATION

1995 - Greek Board of Rheumatology, Diplomate.

MEDICAL LICENCURE

June 1995 - Licenced Rheumatologist, Athens, Greece.

CURRENT PROFESSIONAL POSITION

2012- : Associate Professor of Internal Medicine/Rheumatology, University of Patras Medical School, Patras, Greece.

PREVIOUS ACADEMIC POSTS

1997-1999 Assistant Professor of Medicine, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, USA.

1999- 2002 Adjunct Assistant Professor of Medicine, USUHS

2002-2006 Lecturer, Int. Medicine/Rheumatology, University of Patras Medical School

2007-2012 Assistant Professor (tenured), Medicine/Rheumatology, University of Patras Medical School

HONORS / AWARDS

1995-1996 Award of the Hellenic Society for Rheumatology for studies abroad

1998 **John F. Maher** Award (USA) for Research Excellence

PROFESSIONAL SOCIETIES

1995- Member of the Hellenic Society for Rheumatology

1998- Fellow Member of the American College of Rheumatologists (ACR).

TEACHING ACTIVITIES

Rheumatic Diseases (3rd year Med. Students)

History Taking & Physical Examination (2nd - 4th year Med. Students)

Physical Examination of the Rheumatic patient (5th and 6th year Med students)

USUHS TEACHING ACTIVITIES

Preceptor, ICM-II/ICM-III (1997-1998)

Clinical Concepts (1997-1998)

EDITORIAL ACTIVITIES

Reviewer, *Annals of the Rheumatic Diseases, Arthritis & Rheumatism, The Journal of Immunology, Clinical Immunology (member of the Editorial Board), PLoS One (Academic Editor), Clinical and Diagnostic Laboratory Immunology (member of the*

Editorial Board), *Journal of Rheumatology*, *Rheumatology (Oxford)*, *Journal of Applied Physiology*, *Journal of Investigative Medicine*, *Biological Procedures Online*, *Current Immunology Reviews*, *Clinical Experimental Immunology*

RESEARCH INTERESTS

Human Autoimmunity

Systemic Lupus Erythematosus, Human

Clinical Immunology

T cell physiology

B cell physiology

h-INDEX: 23

Citations: >2,000

BIBLIOGRAPHY

1. **Liossis SNC**, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen-receptor-mediated early signal transduction events. *J Clin Invest* 1996; 98:2549-57.
2. Kovacs B, **Liossis SNC**, Dennis G, Tsokos GC. Increased expression of functional Fas ligand in activated T cells from patients with systemic lupus erythematosus. *Autoimmunity* 1997; 25:213-21.
3. **Liossis SNC**, Ding XZ, Kiang JG, Tsokos GC. Overexpression of the heat-shock protein 70 enhances the TCR/CD3- and the Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. *J Immunol* 1997; 158:5668-75.
4. **Liossis SNC**, Tsokos GC. Heat shock of normal T-cells and T-cell lines downregulates the TCR/CD3-mediated cytoplasmic Ca²⁺ responses and the production of inositol trisphosphate. *Immunopharmacol Immunotoxicol* 1997; 19:511-21.

5. Tsokos GC, Kovacs B, **Liossis SNC**. Lymphocytes, cytokines, inflammation and immune trafficking in SLE. *Curr Opin Rheumatol* 1997; 9:380-6.
6. **Liossis SNC**, Vassilopoulos D, Kovacs B, Tsokos GC. Immune cell biochemical abnormalities in systemic lupus erythematosus. *Clin Exp Rheumatol* 1997; 15:677-84.
7. **Liossis SNC**, Via CS, Tsokos GC. The *alter ego* of heat shock proteins. (**Editorial**) *Clin Immunol Immunopathol* 1998; 86:235-6.
8. **Liossis SNC**, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T-cell receptor zeta chain. *J Clin Invest* 1998; 101:1448-57.
9. **Liossis SNC**, Sfrikakis PP, Tsokos GC. Immune cell signaling aberrations in human lupus. *Immunol Res* 1998; 18:27-39.
10. Tsokos GC, **Liossis SNC**. Lymphocytes, cytokines, inflammation and immune trafficking in SLE. *Curr Opin Rheumatol* 1998; 10:417-25.
11. **Liossis SNC**, Hoffman RW, Tsokos GC. Abnormal early TCR/CD3-mediated signaling events of a snRNP- autoreactive lupus T-cell clone. *Clin Immunol Immunopathol* 1998; 88:305-10.
12. **Liossis SNC**, Tsokos GC. Cellular immunity in osteoarthritis: novel concepts for an old disease. **Commentary**. *CDLI* 1998; 5:427-9.
13. Tsokos GC, **Liossis SNC**. Immune cell signalling in lupus: activation, anergy and death. *Immunol Today* 1999; 20:119-24.
14. **Liossis SNC**, Kovacs B, Gist I, Tsokos GC. Crosslinking of Fas/CD95 suppresses the CD3-mediated signaling events in Jurkat T cells by inhibiting the association of the T-cell receptor ζ chain with the src-protein tyrosine kinases and ZAP-70. *Apoptosis* 1999; 4:327-334.
15. **Liossis SNC**, Tsokos GC. Molecular aspects in the pathogenesis of systemic lupus erythematosus. *Arch Immunol Ther Exp* 2000; 48:11-19.

16. **Liossis SNC**, Sfrikakis PP, Tsokos GC. Signal transduction aberrations in SLE immune cells. *Hellenic Medical Journal*. 1999.
17. **Liossis SNC**, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis M, Sfrikakis PP. B-cell kinase Lyn deficiency in patients with systemic lupus erythematosus. *J Investig Med* 2001; 49:157-165.
18. Enyedy EJ, Nambiar MP, **Liossis SNC**, Dennis GJ, Kammer GM, Tsokos GC. Fc epsilon receptor type I α chain replaces the deficient T cell receptor α chain in T cells from patients with systemic lupus erythematosus. *Arthritis Rheum* 2001; 44:1114-1121.
19. Katsiari CG, **Liossis SN**, Souliotis VL, Dimopoulos MA, Manoussakis MN, Sfrikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. *Clinical Immunology* 2002; 103:54-62.
20. Katsiari CG, **Liossis SN**, Dimopoulos AM, Charalambopoulos DV, Mavrikakis M, Sfrikakis PP. CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition. *Lupus* 2002; 11:370-8.
21. Katopodis O, **Liossis SN**, Viglis V, Pouli A, Dimopoulos MA, Sfrikakis PP. Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma. *Br J Haematol* 2003; 120:478-81.
22. **Liossis SN**, Zouali M. B lymphocyte selection and survival in systemic lupus. *Int Arch Allergy Immunol* 2004; 133:72-83.
23. **Liossis SN**, Sfrikakis PP. Costimulation blockade in the treatment of the rheumatic diseases. *BioDrugs* 2004; 18:95-102.
24. Papapetropoulos S, Argyriou AA, **Liossis SN**, Daousis D, Katsoulas G, Apostolopoulos D, Chroni E. A case of L-dopa responsive Parkinsonian syndrome after low-dose oral methotrexate intake. *Clin Neuropharmacol* 2004; 27:95-98.
25. Daoussis D, Andonopoulos AP, **Liossis SN**. Targeting CD40L: A promising therapeutic approach? *Clin Diagn Lab Immunol* 2004; 11:635-641.

26. Leonardou A, Giali S, Daoussis D, Siambi V, Gogos C, **Liossis SN**. Moraxella catarrhalis-induced septic arthritis of a prosthetic knee joint in a patient with rheumatoid arthritis treated with anakinra. Arthritis Rheum 2005; (letter) In Press.
27. **Liossis SN**, Andonopoulos AP. Autonomic nervous system dysfunction in Sjögren's syndrome. Curr Rev Rheumatol 2005; In Press.
28. **Liossis SN**, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves early clinically evident scleroderma lung disease. Rheumatology 2006; 45:1005-8.
29. **Liossis SN**, Solomou EE, Sfikakis PP. Lyn deficiency in B cells from patients with systemic lupus erythematosus. Arthritis and Rheumatism 2006; 54:2036-7 (letter).
30. Daoussis D, Antonopoulos I, Andonopoulos AP, **Liossis SN**. Increased expression of CD154 (CD40L) on stimulated T cells from patients with psoriatic arthritis. Rheumatology 2007; 46:227-31.
31. Yiannopoulos G, Pastromas V, Antonopoulos I, Katsiberis G, Kalliolias G, **Liossis SN**, Andonopoulos AP. Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatology International 2007; 27:357-61.
32. Starakis I, Mazokopakis E, Siagris D, **Liossis S**, Karatza C, Antonopoulos A. Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal infarction. Rheumatology International 2007; 27:781-3.
33. Kalliolias G, Georgiou PE, Antonopoulos I, Andonopoulos AP, **Liossis SN**. Anakinra treatment in patients with Adult Onset Still's Disease is fast, effective and steroid-sparing: experience from an uncontrolled trial. Annals of the Rheumatic Diseases 2007; 66:842-3.

34. Euthymiopoulou K, Aletras AJ, Ravazoula P, Niarakis A, Daoussis D, Antonopoulos I, **Liossis SN**, Andonopoulos AP. Antiovarian antibodies in primary Sjogren's syndrome.
Rheumatology International 2007; 27:1149-55.
35. Assimakopoulos S, Dimitropoulou D, **Liossis SN**. Intestinal vasculitis in systemic lupus erythematosus.
Journal of Gastroenterology and Hepatology 2008; 23:992.
36. **Liossis SN**, Sfrikakis PP. Rituximab-induced B-cell depletion in autoimmune diseases: potential effects on T cells
Clinical Immunology 2008; 127:280-5.
37. Kallioliadis GD, **Liossis SN**. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Expert Opinion on Investigational Drugs 2008; 17:349-59.
38. Daoussis D, Siambi V, **Liossis SN**, Yannopoulos G, Andonopoulos AP. Bony ears.
Arthritis & Rheumatism 2008; 58:611.
39. Katsiari CG, **Liossis SN**, Sfrikakis PP. The pathophysiologic role of macrophages in systemic lupus erythematosus: a reappraisal.
Seminars in Arthritis & Rheumatism 2010;39:491-503.
40. Daoussis D, **Liossis SN**[¶], Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with Rituximab in scleroderma. A 1-year proof-of-principle study.
Rheumatology 2010; 49:271-80 (E-pub: May 2009).
¶ Equally first author.
41. Daoussis D, **Liossis SN**[¶], Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Evidence that Dickkopf-1 is dysfunctional in ankylosing spondylitis.
Arthritis and Rheumatism 2010; 62; 150-8.
¶ Equally First author.

42. Daoussis D, **Liossis SN**, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Korfiatis P, Yiannopoulos G, Andonopoulos AP. Is there a role for B cell depletion as therapy in scleroderma? A case report and review of the literature.
Seminars in Arthritis and Rheumatism 2009; DOI: 10.1016/j.semarthrit.2009.09.003.
43. Crispin JC, **Liossis SN**, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: recent advances.
Trends in Molecular Medicine 2010; 12:47-57.
44. Daoussis D, **Liossis SN**, Andonopoulos AP. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.
Seminars in Arthritis & Rheumatism 2010; 39:369-83.
45. Karampetsou MP, **Liossis SN**, Sfikakis PP. TNF- α antagonists beyond approved indications: stories of success and prospects for the future.
Quarterly Journal of Medicine 2010; 103:917-28.
46. Karampetsou MP, Andonopoulos AP, **Liossis SN**. Treatment with TNF α blockers induces phenotypical and functional aberrations in peripheral B cells.
Clinical Immunology 2011; 140:8-17.
47. Daoussis D, **Liossis SN**, Yiannopoulos G, Andonopoulos AP. B cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence.
International Journal of Rheumatology 2011; 214013.

ABSTRACTS

* Podium presentations

1. ***Liossis SNC**. A man with spinal hydatid disease. Proceedings of the XIII EULAR Congress; (Abstract) Amsterdam, The Netherlands, June 18-23, 1995.
2. **Liossis SNC**, Kovacs B, Dennis G, Kammer GM, Tsokos GC. Cell signaling in human lupus lymphocytes: Lupus B cells display increased sIgM and sIgD-mediated free intracytoplasmic calcium responses. Arthritis and Rheum. (Abstract) 39, S250, 1996.

3. **Liossis SNC**, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells with systemic lupus erythematosus display abnormal antigen-receptor-mediated early signal transduction events. J. All. Clin. Immunol. (Abstract) 99, S23, 1997.
4. Kovacs B, **Liossis SNC**, Tsokos GC. Crosslinking of the Fas antigen suppresses the CD3-mediated signaling events in T cells by inhibiting the association of the p56lck protein tyrosine kinase with the zeta chain of the T cell receptor. J. Invest. Med. (Abstract) 45, 229A, 1997.
5. **Liossis SNC**, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells with systemic lupus erythematosus display abnormal antigen-receptor-mediated early signal transduction events. J. Invest. Med. (Abstract) 45, 243A, 1997.
6. **Liossis SNC**, Ding XZ, Kiang JG, Tsokos GC. Overexpression of the heat-shock-protein 70 enhances the TCR/CD3- and the Fas/APO-1/CD95-mediated apoptotic cell death in Jurkat T cells. J. Invest. Med. (Abstract) 45, 229A, 1997.
7. **Liossis SNC**, Ding XZ, Dennis GJ, Tsokos GC. Defective T cell receptor ζ chain expression and abnormal T cell signaling in patients with systemic lupus erythematosus. J. Invest. Med. (Abstract) 45, 243A, 1997.
8. **Liossis SNC**, Ding XZ, Kiang JG, Tsokos GC. Overexpression of the heat-shock-protein 70 enhances the TCR/CD3- and the Fas/APO-1/CD95-mediated apoptotic cell death in Jurkat T cells. Arthritis Rheum. (Abstract) 40, S178, 1997.
9. ***Liossis SNC**, Ding XZ, Dennis GJ, Tsokos GC. Defective T cell receptor ζ chain expression and abnormal T cell signaling in patients with systemic lupus erythematosus. (**Plenary Session**) Arthritis Rheum. (Abstract) 40, S72, 1997.
10. Kovacs B, **Liossis SNC**, Dennis GJ, Tsokos GC. Increased expression of functional Fas ligand in activated cells from patients with systemic lupus erythematosus. In: Novel perspectives on Systemic Lupus Erythematosus: From Basic Research to Clinical Applications, NIH Conference, NIH Bethesda, MD, Nov. 6-8, 1997.
11. **Liossis SNC**, Ding XZ, Dennis GJ, Tsokos GC. Defective T cell receptor ζ chain expression and abnormal T cell signaling in patients with systemic lupus erythematosus. In: Novel

perspectives on Systemic Lupus Erythematosus: From Basic Research to Clinical Applications, NIH Conference, NIH, Bethesda, MD, Nov. 6-8, 1997.

12. **Liossis SNC**, Ding XZ, Dennis GJ, Tsokos GC. Abnormal anti-CD3-mediated protein tyrosine phosphorylation in T cells from patients with SLE and deficient expression of the TCRzeta chain. FASEB J. (Abstract) 12, A1094, 1998.
13. **Liossis SNC**, Dimopoulos MA, Sfrikakis PP. Expression of the B cell inhibitory molecule CD22 in patients with systemic lupus erythematosus. American College of Rheumatology Basic Sciences Conference, Boston, November 1999. Arthritis Rheum. (Abstract) S55, 1999.
14. Katsiari CG, **Liossis SNC**, Dimopoulos MA, Mavrikakis M, Sfrikakis PP. Resistance of TCR-mediated CD40L expression on SLE T cells to cyclosporine A. American College of Rheumatology Basic Sciences Conference, Boston, November 1999. Arthritis Rheumatism. (Abstract) S54, 1999.
15. **Liossis SNC**, Mavrikakis M, Dimopoulos MA, Sfrikakis PP. Expression of B cell signaling regulatory molecules in patients with systemic lupus erythematosus. Arthritis Rheum. (Abstract) S309, 1999.
16. Katsiari CG, **Liossis SNC**, Dimopoulos MA, Mavrikakis M, Sfrikakis PP. Resistance of TCR-mediated CD40L expression on SLE T cells to cyclosporine A. Arthritis Rheumatism. (Abstract) S102, 1999.

BOOK CHAPTERS

1. **Liossis SNC**, Tsokos GC. B cells in SLE. *In*: Lupus: Cellular and Molecular pathogenesis. Kammer GM, Tsokos GC, eds. Humana Press Inc., Totowa, NJ: 1999.
2. **Liossis SNC**, Tsokos GC. Pathogenesis of lupus. *In*: Molecular Rheumatology. Tsokos GC, ed. Humana Press, Totowa, NJ: 1999; In Press.
3. **Liossis SNC**, Tsokos GC. B-cell abnormalities in SLE. *In*: Dubois Lupus Erythematosus. Wallace, Hahn, ed. 2001, 205-218.
4. **Liossis SNC**, Sfrikakis PP. CTLA-4 in rheumatoid arthritis. *In*: CTLA-4 in autoimmune disease. Eureka Publications, 2002.

5. **Liossis SNC, Tsokos GC.** B cell abnormalities in systemic lupus erythematosus. In: **Dubois Lupus Erythematosus.** Wallace JD, Hahn BH, eds., 7th ed. Lippincott Williams & Wilkins, 2007, 176-90.
6. **Liossis SNC, Tsokos GC.** B cells in Human Systemic Lupus Erythematosus. In: A companion to **Rheumatology.** Systemic Lupus Erythematosus. Tsokos GC, Gordon C, Smolen JS, eds., 1st ed. Mosby Elsevier, 2007; 103-8.